You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site.


Go back

Combodart Indications

Combodart is indicated for the management of moderate to severe symptomatic benign prostatic
hyperplasia (BPH).
Combodart (dutasteride/tamsulosin hydrochloride) is the only registered fixed dose combination in Ireland for the treatment of moderate to severe BPH symptoms.
It is a combination of two medicines, dutasteride and tamsulosin hydrochloride.


  • lowers DHT levels,
  • reduces prostate volume,
  • improves lower urinary tract symptoms and urine flow
  • reduces the risk of Acute Urinary Retention (AUR) and BPH related surgery.


  • increases maximum urinary flow rate by reducing smooth muscle tension in the prostate and urethra, thereby relieving obstruction.
  • improves the complex of irritative and obstructive symptoms in which bladder instability and tension of the smooth muscles of the lower urinary tract play an important role.
  • Alpha-1 adrenergic blockers can reduce blood pressure by lowering peripheral resistance

Sample Patient Profile

The following profile is an example of a patient type bothered by moderate BPH symptoms, including an enlarged prostate and impacted quality of life, whom you can start with Combodart.
This is a fictitious patient representing the CombAT study population1
IPSS = International Prostate Symptom Score.
PVol = Prostate Volume.

John – Moderate BPH

image of John


  • I get up to go to the toilet 2 to 3 times a night. It’s not only me that’s not rested, my partner also never gets a decent night’s sleep either
  • I have to go to the toilet a lot during the day. 
  • I try to avoid long meetings now as having to excuse myself repeatedly looks unprofessional
  • I spend more time in the toilet. It’s embarrassing taking so long, because of my weak urinary stream

Clinical profile:

  • IPSS: 16
  • PVol: 40cc
  • PSA: 1.9ng/mL


  1. Roehrborn CG et al. Eur Urol 2010; 57: 123–131.

Combodart is registered trademark of the GlaxoSmithKline Group of companies